| pubmed-article:1967522 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1967522 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:1967522 | lifeskim:mentions | umls-concept:C0022646 | lld:lifeskim |
| pubmed-article:1967522 | lifeskim:mentions | umls-concept:C0023890 | lld:lifeskim |
| pubmed-article:1967522 | lifeskim:mentions | umls-concept:C0178601 | lld:lifeskim |
| pubmed-article:1967522 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1967522 | lifeskim:mentions | umls-concept:C0123043 | lld:lifeskim |
| pubmed-article:1967522 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:1967522 | pubmed:dateCreated | 1990-2-12 | lld:pubmed |
| pubmed-article:1967522 | pubmed:abstractText | We investigated the renal and humoral effects of short-term administration of ibopamine, an orally active dopamine agonist, in patients with liver cirrhosis. The patients were divided into two groups on the basis of sodium excretion with a constant sodium intake of 40 mEq/d. We also compared the effects of ibopamine with those induced by intravenous infusion of dopamine hydrochloride (3 micrograms/kg per minute) in similar patients. Ibopamine caused significant increases in urine output, glomerular filtration rate, and sodium excretion throughout the 4 hours of the trial in patients with basal sodium excretion rate greater than 20 mmol/d. These renal effects were associated with a significant reduction in plasma aldosterone concentration. In contrast, only a transient increase in glomerular filtration rate and a diminution in plasma aldosterone concentration were observed after ibopamine in the patients with a basal sodium excretion rate less than 20 mmol/d. The infusion of dopamine had renal effects similar to those of ibopamine in both groups of patients. These results indicate that in cirrhotic patients with normal sodium excretion, ibopamine exerts a diuretic and natriuretic effect similar to that of dopamine infusion. However, these properties of dopaminergic agents are apparently lost in patients with avid sodium retention. | lld:pubmed |
| pubmed-article:1967522 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1967522 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1967522 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:1967522 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1967522 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1967522 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1967522 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1967522 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1967522 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1967522 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1967522 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:1967522 | pubmed:issn | 0003-9926 | lld:pubmed |
| pubmed-article:1967522 | pubmed:author | pubmed-author:GrazianiGG | lld:pubmed |
| pubmed-article:1967522 | pubmed:author | pubmed-author:MorgantiAA | lld:pubmed |
| pubmed-article:1967522 | pubmed:author | pubmed-author:GhirardiPP | lld:pubmed |
| pubmed-article:1967522 | pubmed:author | pubmed-author:SalernoFF | lld:pubmed |
| pubmed-article:1967522 | pubmed:author | pubmed-author:LorenzanoEE | lld:pubmed |
| pubmed-article:1967522 | pubmed:author | pubmed-author:BadalamentiSS | lld:pubmed |
| pubmed-article:1967522 | pubmed:author | pubmed-author:IncertiPP | lld:pubmed |
| pubmed-article:1967522 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1967522 | pubmed:volume | 150 | lld:pubmed |
| pubmed-article:1967522 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1967522 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1967522 | pubmed:pagination | 65-9 | lld:pubmed |
| pubmed-article:1967522 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1967522 | pubmed:meshHeading | pubmed-meshheading:1967522-... | lld:pubmed |
| pubmed-article:1967522 | pubmed:meshHeading | pubmed-meshheading:1967522-... | lld:pubmed |
| pubmed-article:1967522 | pubmed:meshHeading | pubmed-meshheading:1967522-... | lld:pubmed |
| pubmed-article:1967522 | pubmed:meshHeading | pubmed-meshheading:1967522-... | lld:pubmed |
| pubmed-article:1967522 | pubmed:meshHeading | pubmed-meshheading:1967522-... | lld:pubmed |
| pubmed-article:1967522 | pubmed:meshHeading | pubmed-meshheading:1967522-... | lld:pubmed |
| pubmed-article:1967522 | pubmed:meshHeading | pubmed-meshheading:1967522-... | lld:pubmed |
| pubmed-article:1967522 | pubmed:meshHeading | pubmed-meshheading:1967522-... | lld:pubmed |
| pubmed-article:1967522 | pubmed:meshHeading | pubmed-meshheading:1967522-... | lld:pubmed |
| pubmed-article:1967522 | pubmed:meshHeading | pubmed-meshheading:1967522-... | lld:pubmed |
| pubmed-article:1967522 | pubmed:meshHeading | pubmed-meshheading:1967522-... | lld:pubmed |
| pubmed-article:1967522 | pubmed:meshHeading | pubmed-meshheading:1967522-... | lld:pubmed |
| pubmed-article:1967522 | pubmed:meshHeading | pubmed-meshheading:1967522-... | lld:pubmed |
| pubmed-article:1967522 | pubmed:meshHeading | pubmed-meshheading:1967522-... | lld:pubmed |
| pubmed-article:1967522 | pubmed:meshHeading | pubmed-meshheading:1967522-... | lld:pubmed |
| pubmed-article:1967522 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:1967522 | pubmed:articleTitle | Renal and humoral effects of ibopamine, a dopamine agonist, in patients with liver cirrhosis. | lld:pubmed |
| pubmed-article:1967522 | pubmed:affiliation | Institute of Internal Medicine, University of Milan Medical School, Italy. | lld:pubmed |
| pubmed-article:1967522 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1967522 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1967522 | lld:pubmed |
